Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ: IRWD · IEX Real-Time Price · USD
8.71
+0.09 (1.04%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.

It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.

The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.

The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.

Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals logo
Country United States
Founded 1998
IPO Date Feb 3, 2010
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 267
CEO Thomas A. McCourt

Contact Details

Address:
100 Summer Street, Suite 2300
Boston, Massachusetts 02110
United States
Phone 617-621-7722
Website ironwoodpharma.com

Stock Details

Ticker Symbol IRWD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001446847
CUSIP Number 46333X108
ISIN Number US46333X1081
Employer ID 04-3404176
SIC Code 2834

Key Executives

Name Position
Julie H. McHugh Executive Chairman of the Board
Thomas A. McCourt Chief Executive Officer and Director
Sravan Kumar Emany Senior Vice President, Principal Financial Officer and Chief Financial Officer
John Minardo Senior Vice President, Chief Legal Officer and Secretary
Dr. Michael Shetzline M.D., Ph.D. Chief Medical Officer, Senior Vice President and Head of Research and Drug Development
Ronald Silver Corporate Controller and Principal Accounting Officer
Marcel Moulaison Vice President of Technical Operations
Greg Martini Vice President of Strategic Finance and Investor Relations
Beth Calitri Head of Corporate Communications and Media Relations
Mike Nanfito Vice President of Sales and Sales Excellence

Latest SEC Filings

Date Type Title
Feb 16, 2024 10-K Annual Report
Feb 15, 2024 8-K Current Report
Feb 9, 2024 144 Filing
Feb 9, 2024 144 Filing
Feb 9, 2024 144 Filing
Feb 9, 2024 144 Filing
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals